Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study.
Di Lorenzo
Giuseppe
G
Kreuter
Alexander
A
Di Trolio
Rossella
R
Guarini
Attilio
A
Romano
Carmela
C
Montesarchio
Vincenzo
V
Brockmeyer
Norbert H
NH
De Placido
Sabino
S
Bower
Mark
M
Dezube
Bruce J
BJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use* / Q000633:toxicity; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000628:therapy*; D016896:Treatment Outcome
C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin